Lars Jørgen Østergaard

Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial. / Høgh, Annette Langager; Vammen, Steen; Østergaard, Lars Jørgen; Joensen, Jette B; Henneberg, Esklid W; Lindholt, Jes S.

In: Vascular and Endovascular Surgery, Vol. 43, No. 5, 2009, p. 452-456.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Høgh, Annette Langager ; Vammen, Steen ; Østergaard, Lars Jørgen ; Joensen, Jette B ; Henneberg, Esklid W ; Lindholt, Jes S. / Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial. In: Vascular and Endovascular Surgery. 2009 ; Vol. 43, No. 5. pp. 452-456.

Bibtex

@article{31bf3dc0c93511dea30a000ea68e967b,
title = "Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial",
abstract = "Background: Antibodies against Chlamydia pneumoniae are associated with an increased rate of expansion of small abdominal aortic aneurysms (AAAs). Short-term follow-up trials have shown a transient reduction AAA growth rate, in macrolide treated compared with placebo. Therefore we analysed the influence of intermittent, long-term roxithromycin treatment on AAA expansion and referral for surgery. Methods: Eighty-four patients with small AAAs were randomized to either an annual 4 weeks' treatment with roxithromycin or placebo, and followed prospectively. Results: Intermittent, long-term Roxithromycin-treatment reduced mean annual growth rate by 36% compared with placebo after adjustment for potential confounders. Long-term roxithromycin-treated patients had a 29% lower risk of being referred for surgical evaluation, increasing to 57% after adjusting for potential confounders. Conclusion: Annual 4 week treatment with 300 mg roxithromycin daily may reduce the progression of small AAAs, and later need for surgical repair. However, more robust studies are needed for confirmation.",
author = "H{\o}gh, {Annette Langager} and Steen Vammen and {\O}stergaard, {Lars J{\o}rgen} and Joensen, {Jette B} and Henneberg, {Esklid W} and Lindholt, {Jes S.}",
year = "2009",
doi = "10.1177/1538574409335037",
language = "English",
volume = "43",
pages = "452--456",
journal = "Vascular and Endovascular Surgery",
issn = "1538-5744",
publisher = "Sage Publications, Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial

AU - Høgh, Annette Langager

AU - Vammen, Steen

AU - Østergaard, Lars Jørgen

AU - Joensen, Jette B

AU - Henneberg, Esklid W

AU - Lindholt, Jes S.

PY - 2009

Y1 - 2009

N2 - Background: Antibodies against Chlamydia pneumoniae are associated with an increased rate of expansion of small abdominal aortic aneurysms (AAAs). Short-term follow-up trials have shown a transient reduction AAA growth rate, in macrolide treated compared with placebo. Therefore we analysed the influence of intermittent, long-term roxithromycin treatment on AAA expansion and referral for surgery. Methods: Eighty-four patients with small AAAs were randomized to either an annual 4 weeks' treatment with roxithromycin or placebo, and followed prospectively. Results: Intermittent, long-term Roxithromycin-treatment reduced mean annual growth rate by 36% compared with placebo after adjustment for potential confounders. Long-term roxithromycin-treated patients had a 29% lower risk of being referred for surgical evaluation, increasing to 57% after adjusting for potential confounders. Conclusion: Annual 4 week treatment with 300 mg roxithromycin daily may reduce the progression of small AAAs, and later need for surgical repair. However, more robust studies are needed for confirmation.

AB - Background: Antibodies against Chlamydia pneumoniae are associated with an increased rate of expansion of small abdominal aortic aneurysms (AAAs). Short-term follow-up trials have shown a transient reduction AAA growth rate, in macrolide treated compared with placebo. Therefore we analysed the influence of intermittent, long-term roxithromycin treatment on AAA expansion and referral for surgery. Methods: Eighty-four patients with small AAAs were randomized to either an annual 4 weeks' treatment with roxithromycin or placebo, and followed prospectively. Results: Intermittent, long-term Roxithromycin-treatment reduced mean annual growth rate by 36% compared with placebo after adjustment for potential confounders. Long-term roxithromycin-treated patients had a 29% lower risk of being referred for surgical evaluation, increasing to 57% after adjusting for potential confounders. Conclusion: Annual 4 week treatment with 300 mg roxithromycin daily may reduce the progression of small AAAs, and later need for surgical repair. However, more robust studies are needed for confirmation.

U2 - 10.1177/1538574409335037

DO - 10.1177/1538574409335037

M3 - Journal article

C2 - 19640922

VL - 43

SP - 452

EP - 456

JO - Vascular and Endovascular Surgery

JF - Vascular and Endovascular Surgery

SN - 1538-5744

IS - 5

ER -